Cell Medica Targeting Next CAR-T Wave: Solid Tumor Anticancers
Executive Summary
Cell Medica has just raised a large Series C from UK institutional investors to explore the use of novel cell-based immunotherapies in solid tumors, a “new chapter” for this class of therapeutic agents.
You may also be interested in...
Touchstone Plays Tough As IP Group Ups Bid To £490m
One of the key attractions is Touchstone's holdings in Imperial College spin-offs such as Cell Medica, Circassia Pharmaceuticals and TopiVert Pharma.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.